SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB
          QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                       FOR THE QUARTER ENDED JUNE 30, 2005


                             COMMISSION FILE NUMBER:

                             BV PHARMACEUTICAL, INC.
             ------------------------------------------------------
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                     NEVADA
         --------------------------------------------------------------
         (State or other jurisdiction of incorporation or organization)

                  Nevada                           72-1580091
          -----------------------     ------------------------------------
          (State of organization)     (I.R.S. Employer Identification No.)


                           2890 Vassar Street, Suite A
                                 Reno, NV 89502

                    ----------------------------------------
                    (Address of principal executive offices)


                                Tel: 775.352.4160
                -------------------------------------------------
                Registrants telephone number, including area code

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act  during  the past 12  months  and (2) has been
subject to such filing  requirements  for the past 90 days.  Yes [x]

Securities registered under Section 12(g) of the Exchange Act:

There are 37,480,100 shares of common stock outstanding as of June 30, 2005


<PAGE>

                                TABLE OF CONTENTS
                                -----------------


PART I       FINANCIAL INFORMATION

ITEM  1      FINANCIAL STATEMENTS

ITEM  2      MANAGEMENT'S DISCUSSION OF OPERATIONS AND FINANCIAL CONDITION

PART II      OTHER INFORMATION

ITEM 7       SIGNATURES


<PAGE>


                             BV PHARMACEUTICAL, INC.

                          (A Development Stage Company)

                          INTERIM FINANCIAL STATEMENTS

                                  June 30, 2005

                             (Stated in US Dollars)

                                   (UNAUDITED)

<PAGE>
<TABLE>
<CAPTION>

                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                             INTERIM BALANCE SHEETS
                       June 30, 2005 and December 31, 2004
                             (Stated in US Dollars)
                                   (UNAUDITED)


                                                                                    June 30,         December 31,
                                      ASSETS                                          2005               2004
                                                                               -----------------   ---------------
<S>                                                                            <C>                 <C>
Current
   Cash                                                                        $          10,095   $        24,964
   Accounts receivable                                                                     2,000             2,000
                                                                               -----------------   ---------------
                                                                               $          12,095   $        26,964
                                                                               =================   ===============
                                   LIABILITIES

Current
   Accounts payable and accrued liabilities                                    $           5,255   $         8,517
   Current portion of convertible debentures - Note 3                                     50,000            50,000
   Unearned revenue                                                                        7,500                 -
                                                                               -----------------   ---------------
                                                                                          62,755            58,517

Convertible debentures - Notes 3 and 5                                                     7,271             4,792
                                                                               -----------------   ---------------
                                                                                          70,026            63,309

                            STOCKHOLDERS' DEFICIENCY

Capital stock - Notes 3, 4 and 5 Authorized:
           75,000,000  common shares, $0.001 par value
   Issued:
           37,480,100  common shares (December 31, 2004: 37,480,100)                      37,480            37,480
Additional paid-in capital                                                                62,495            62,495
Deficit accumulated during the development stage                                        (157,906)         (136,320)

                                                                                         (57,931)          (36,345)
                                                                               -----------------   ---------------
                                                                               $          12,095   $        26,964
                                                                               =================   ===============

</TABLE>

                             SEE ACCOMPANYING NOTES

<PAGE>

<TABLE>
<CAPTION>

                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                        INTERIM STATEMENTS OF OPERATIONS
                    for the three and six month periods ended
               June 30, 2005 and 2004 and for the period from June
                30, 2000 (Date of Incorporation) to June 30, 2005
                             (Stated in US Dollars)
                                   (UNAUDITED)



                                                                                                                June 30, 2000
                                                                                                                   (Date of
                                                                                                                Incorporation)
                                              Three months ended                   Six months ended                   to
                                                   June 30,                            June 30,                    June 30,
                                            2005              2004              2005              2004               2005
                                      ----------------  ----------------  ----------------  ----------------  ----------------
<S>                                   <C>               <C>               <C>               <C>               <C>
Revenue
   Licence fees                       $              -  $          4,000  $              -  $         10,000  $         24,000
   Other income                                      -                 -               480                13             1,738
                                      ----------------  ----------------  ----------------  ----------------  ----------------
                                                     -             4,000               480            10,013            25,738
                                      ----------------  ----------------  ----------------  ----------------  ----------------

General and administrative
 expenses
   Advertising and promotion                         -                 -                 -                 -             1,001
   Consulting fees                                   -             5,900                 -             7,400            48,072
   Filing fees                                   1,566               680             6,613             2,047            11,364
   Interest and bank charges                     1,276             1,302             2,564             2,443             7,569
   Investor relations                                -                 -                 -                 -             9,996
   Office and miscellaneous                      1,146               460             3,425             1,260            10,571
   Marketing research and
    development                                      -                 -                 -                 -            10,000
   Professional fees                             2,388             1,000             7,610             3,885            30,856
   Rent                                              -                 -                 -                 -               505
   Transfer agent fees                             481                 -             1,581                 -             1,581
   Intellectual property
    acquisition costs                                -                 -                 -                 -            50,000
   Website                                         273               650               273               650             2,129
                                      ----------------  ----------------  ----------------  ----------------  ----------------
                                                 7,130             9,992            22,066            17,685           183,644
                                      ----------------  ----------------  ----------------  ----------------  ----------------
Net loss for the period               $         (7,130) $         (5,992) $        (21,586) $         (7,672) $       (157,906)
                                      ================  ================  ================  ================  ================

Basic loss per share                  $         (0.00)  $         (0.00)  $         (0.00)  $         (0.00)
                                      ================  ================  ================  ================
Weighted average number of
 shares outstanding                         37,480,100        37,480,100        37,480,100        37,480,100
                                      ================  ================  ================  ================

</TABLE>


                             SEE ACCOMPANYING NOTES

<PAGE>
<TABLE>
<CAPTION>


                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                        INTERIM STATEMENTS OF CASH FLOWS
                    for the six month periods ended June 30,
               2005 and 2004 and for the period from June 30, 2000
                    (Date of Incorporation) to June 30, 2005
                             (Stated in US Dollars)
                                   (UNAUDITED)


                                                                                                           June 30, 2000
                                                                                                              (Date of
                                                                              Six months ended           Incorporation) to
                                                                                  June 30,                    June 30,
                                                                            2005            2004                2005
                                                                       --------------  ---------------  ------------------
<S>                                                                    <C>             <C>              <C>
Cash flows used in Operating Activities
   Net loss for the period                                             $     (21,586)  $       (7,672)  $        (157,906)
   Changes in non-cash working capital balances related to
    operations:
      Accounts receivable                                                          -           (3,000)             (2,000)
      Accounts payable and accrued liabilities                                (3,262)           1,385               5,255
      Unearned revenue                                                         7,500                -               7,500
                                                                       --------------  ---------------  ------------------
                                                                             (17,348)          (9,287)           (147,151)
                                                                       --------------  ---------------  ------------------

Cash flows from Financing Activities
   Capital stock issued                                                            -                -              99,975
   Increase in convertible debentures                                          2,479           52,288              57,271
                                                                       --------------  ---------------  ------------------
                                                                               2,479           52,288             157,246
                                                                       --------------  ---------------  ------------------
Increase (decrease) in cash                                                  (14,869)          43,001              10,095

Cash, beginning of the period                                                 24,964            3,708                   -
                                                                       --------------  ---------------  ------------------
Cash and cash equivalents, end of the period                           $      10,095   $       46,709   $          10,095
                                                                       ==============  ===============  ==================

Supplemental disclosure of cash flow information Cash paid for:
      Interest                                                         $           -   $            -   $               -
                                                                       ==============  ===============  ==================

      Income taxes                                                     $           -   $            -   $               -
                                                                       ==============  ===============  ==================
 Cash and cash equivalents consist of:
   Cash                                                                $      10,095   $       21,709
   Term deposit                                                                    -           25,000
                                                                       -------------   --------------
                                                                       $      10,095   $       46,709
                                                                       =============   ==============

</TABLE>

                             SEE ACCOMPANYING NOTES

<PAGE>
<TABLE>
<CAPTION>


                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                       INTERIM STATEMENT OF STOCKHOLDERS'
                   EQUITY (DEFICIENCY) for the period June 30,
                  2000 (Date of Incorporation) to June 30, 2005
                             (Stated in US Dollars)
                                   (UNAUDITED)


                                                                                                     DEFICIT
                                                                                                   ACCUMULATED
                                                                                    ADDITIONAL     DURING THE
                                                            COMMON STOCK             PAID-IN       DEVELOPMENT
                                                      * SHARES    ** PAR VALUE       CAPITAL         STAGE           TOTAL
                                                      ----------  --------------  -------------  --------------  ----------------
<S>                                                   <C>         <C>             <C>            <C>             <C>
Capital stock subscribed pursuant to an offering
 memorandum for cash              - at $0.000007      30,543,000  $       30,543  $     (30,339) $            -  $            204
                                                      ----------  --------------  -------------  --------------  ----------------

Balance, December 31, 2000                            30,543,000          30,543        (30,339)              -               204

Capital stock issued pursuant to a private
 placement                            - at $0.01       6,777,100           6,777         60,994               -            67,771
                                      - at $0.20          40,000              40          7,960               -             8,000
Net loss for the year                                          -               -              -         (69,885)          (69,885)
                                                      ----------  --------------  -------------  --------------  ----------------
Balance, December 31, 2001                            37,360,100          37,360         38,615         (69,885)            6,090

Capital stock issued pursuant to a private
 placement                            - at $0.20         120,000             120         23,880               -            24,000
Net loss for the year                                          -               -              -         (30,090)          (30,090)
                                                      ----------  --------------  -------------  --------------  ----------------

Balance, December 31, 2002                            37,480,100          37,480         62,495         (99,975)                -
Net income for the year                                        -               -              -             108               108
                                                      ----------  --------------  -------------  --------------  ----------------

Balance, December 31, 2003                            37,480,100          37,480         62,495         (99,867)              108
Net loss for the year                                          -               -              -         (36,453)          (36,453)
                                                      ----------  --------------  -------------  --------------  ----------------

Balance, December 31, 2004                            37,480,100          37,480         62,495        (136,320)          (36,345)
Net loss for the period                                        -               -              -         (21,586)          (21,586)
                                                      ----------  --------------  -------------  --------------  ----------------

Balance, June 30, 2005                                37,480,100  $       37,480  $      62,495  $     (157,906) $        (57,931)
                                                      ==========  ==============  =============  ==============  ================
</TABLE>

 *  The common  stock  issued has been  retroactively  restated to reflect a
    forward  stock split of 1,500 new shares for one old share  effective on
    January 5, 2001.

**  The par value of common stock has been retroactively restated to reflect
    a change from no par value to a par value of $0.001 per share.


                             SEE ACCOMPANYING NOTES

<PAGE>

                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                    NOTES TO THE INTERIM FINANCIAL STATEMENTS
                                  June 30, 2005
                             (Stated in US Dollars)
                                   (UNAUDITED)

Note 1        INTERIM REPORTING

              The accompanying  unaudited interim financial statements have been
              prepared by BV  Pharmaceuticals,  Inc. (the "Company") pursuant to
              the rules and  regulations  of the United  States  Securities  and
              Exchange Commission.  Certain information and disclosures normally
              included in annual  financial  statements  prepared in  accordance
              with accounting principles generally accepted in the United States
              of America have been  condensed or omitted  pursuant to such rules
              and regulations. In the opinion of management, all adjustments and
              disclosures  necessary for a fair  presentation of these financial
              statements have been included.  Such adjustments consist of normal
              recurring  adjustments.  These interim financial statements should
              be read in conjunction  with the audited  financial  statements of
              the Company for the fiscal year ended December 31, 2004.

              The results of  operations  for the six months ended June 30, 2005
              are not  indicative  of the results  that may be expected  for the
              full year.

Note 2        CONTINUANCE OF OPERATIONS

              The  interim   financial   statements  have  been  prepared  using
              generally accepted  accounting  principles in the United States of
              America  applicable  for a going  concern  which  assumes that the
              Company will realize its assets and discharge its  liabilities  in
              the ordinary course of business. At June 30, 2005, the Company has
              a working  capital  deficiency  of $50,660,  has not yet  attained
              profitable operations and has accumulated losses of $157,906 since
              its  commencement.  Its ability to continue as a going  concern is
              dependent  upon the ability of the Company to generate  profitable
              operations in the future and/or to obtain the necessary  financing
              to meet  its  obligations  and pay its  liabilities  arising  from
              normal  business  operations  when they come due.  The  outcome of
              these matters  cannot be predicted with any certainty at this time
              and  raise  substantial  doubt  that the  Company  will be able to
              continue as a going  concern.  These  financial  statements do not
              include  any  adjustments  to the amounts  and  classification  of
              assets and liabilities that may be necessary should the Company be
              unable to continue  as a going  concern.  The Company  anticipates
              that  additional  funding will be in the form of equity  financing
              from the sale of  common  shares.  The  Company  may also  seek to
              obtain  short-term loans from the directors of the Company.  There
              are no  current  arrangements  in  place  for  equity  funding  or
              short-term loans.

<PAGE>
<TABLE>
<CAPTION>


Note 3      CONVERTIBLE DEBENTURES - Note 5

                                                                               June 30,       December 31,
                                                                                 2005             2004
                                                                            -------------    -------------
 On           January  15,  2004 the  Company  issued two  convertible
              debentures  in the  principal  amount  of  $25,000  each
              bearing  interest  at 10% per annum and  secured  by the
              general  credit of the  Company.  These  debentures  are
              convertible  into  common  shares of the  Company on the
              basis of $0.20 per common share for each $1 of principal
              and  interest  accrued  thereon,  at the  option  of the
              debenture holder, up to January 15, 2006. Interest shall
              be  payable  at the end of each  calendar  year with the
              first  payment due on December 31, 2007,  in either cash
              or common  shares at the  option of the  holder.  If the
              interest is paid in shares,  then the shares will have a
              deemed value of $2.50 each.

<S>                                                                         <C>             <C>
                                                                            $      57,271   $        54,792

              Less: current portion                                               (50,000)          (50,000)
                                                                            --------------  ----------------
                                                                            $       7,271   $         4,792
                                                                            ==============  ================

</TABLE>


Note 4        CAPITAL STOCK - Notes 3 and 5

              On January 5, 2001,  the Company  approved a forward  split of its
              common  stock on the basis of 1,500 new for 1 old.  The  number of
              shares referred to in these financial statements has been restated
              wherever  applicable  to give  retroactive  effect on the  forward
              stock split.

              On May 25, 2004, the Company amended its authorized  capital stock
              to 75,000,000  common shares with a par value of $0.001 per share.
              The  number of  authorized  shares  and the par value per share as
              referred  to in  these  financial  statements  has  been  restated
              wherever applicable to give retroactive effect to this amendment.

Note 5        SUBSEQUENT EVENT - Notes 3 and 4

              Subsequent to June 30, 2005,  the  convertible  debenture  holders
              gave notice to convert the  outstanding  principal and interest of
              $57,271 at June 30, 2005. As a result,  the Company issued 286,356
              common shares at $0.20 per share.

<PAGE>


ITEM  2      MANAGEMENT'S DISCUSSION OF OPERATIONS AND FINANCIAL CONDITION

DESCRIPTION OF BUSINESS

BV Pharmaceutical,  Inc. is a Nevada corporation, which was originally formed on
June  30,  2000  under  the name of All  Printer  Supplies.com.  As All  Printer
Supplies.com,  the company  sought a  consulting  opportunity  for  products and
supplies to be offered on the  internet,  but the  economy at the time,  due the
demise  of  many  "dot  com"  companies  and  businesses,  and the  poor  market
conditions,  was never  able to launch  its  business.  On April 17,  2003,  the
Company  changed its name to BV  Pharmaceutical,  Inc.  Its  principal  place of
business is located at 2890 Vassar Street,  Suite A, Reno, NV 89502. The Company
was organized to engage in any lawful  corporate  business.  BV  Pharmaceutical,
Inc., has been in the developmental stage since inception and has a very limited
operating  history and  limited  revenues.  The  Company  has a fully  developed
business plan, is operational and receiving revenue. The company has $157,906 in
losses to date.


BV  Pharmaceutical,  Inc has limited  start-up  operations  and is  considered a
development stage Company. The Company was originally capitalized at 100,000,000
shares of Common Stock,  with no par value. On May 25, 2004 the amended Articles
of  Incorporation  were filed with the state of Nevada to decrease the number of
authorized  capital stock to 75,000,000  common shares with $0.001 par value. By
reducing the number of shares and establishing a par values for the shares,  the
Company's annual filing fee with the Nevada Secretary of State was reduced.  The
amendment was a cost-saving  measure only.  The only impact on the  shareholders
was a reduction of the total  authorized  shares.  While this reduced the shares
available for  issuance,  it also limited the possible  dilution  which could be
suffered by the shareholders. The Company believes the amendment had no material
impact on the Company,  its  operations,  proposed  operations  or the rights of
shareholders.


In an effort to  develop  our  business,  we will  seek to  establish  strategic
business  relationships  with  leading  firms.  We  anticipate  these  strategic
relationships  would  involve the  offering  of our  services to the members and
employees  of the  particular  company on a  discounted  basis.  We have not yet
established  the amount of any such  discount.  Initially we intend to focus our
efforts on offering  these services to companies in the  Entertainment,  Sports,
and Biotech industries.  We have not yet identified,  contacted or establish any
relationships with any these companies.

BUSINESS DEVELOPMENT.

We were incorporated in the State of Nevada on June 30, 2000, for the purpose of
providing  consulting  services to businesses,  and engaging in any other lawful
activity.

PRINCIPAL PRODUCTS AND SERVICES

We  currently  have  a web  site  at the  URL  WWW.YOURCLONEGUARD.COM.  We  have
registered a domain name, and have a hosting service for WWW.YOURCLONEGUARD.COM.
Our  Company  and  website  provide  information  and  services  in the areas of
personal DNA collection,  analysis,  profiling, banking and DNA profile database
maintenance.

The website provides  interested  parties:  services,  information and resources
dealing with the collection,  analysis,  protection and banking of ones personal
and unique DNA profile. The website is fully operational, provides access to the
services  discussed above, and allows  interested  parties to place orders.  The
company's  website is limited  to the  services  discussed  above.  Through  our
website,  you will find  information  on such  topics and issues  as:  DNA,  DNA
Patterns  or  Profiles,  DNA  patents,  DNA sample  collection,  confidentiality
aspects of DNA profile  collection,  DNA collection and banking  suitability for
minors,  DNA cloning,  theft and  protection  issues.  In addition you will find
links to other articles and resources of interest.

Through its  website the Company  offers  access to services  for  personal  DNA
collection,  analysis, profiling, banking, and DNA profile database maintenance.
Currently the Company  plans to offer two  services.  The first being an in home
self test DNA Profile Kit with  banking  (storage).  The initial  price for this
service is currently  US$120.  The second service,  performed by a professional,
allows  for the  collection,  analysis,  profiling,  banking,  and  DNA  profile
database  maintenance.  This  service will assist the client in  establishing  a
chain of custody. Through this service the Company will provide secure access to
a client's personal DNA profile,  with documented chain of custody  established,
should at some point in the future the need arise to provide  evidence  of prior
ownership. The initial price for this service is currently US $280.

IN HOME SELF TEST DNA PROFILE KIT AND BANKING.
The Kit will contain buccal sample swabs, sample collection technique indicator,
pre-paid return  envelope,  a collection seal, along with easy to follow step by
step directions to take a sample.

<PAGE>

The sample process of collection is simple, fast, and non-intrusive.  Collection
takes place by way of a home  self-test kit, where a cotton swab (a buccal swab)
is gently  wiped  across  the  inside of the  Client's  cheek.  The swab,  which
contains  your  saliva and the DNA  sample,  is then  labeled  and mailed to the
Company  for  banking  (storage).  The test  process  and  results  would not be
considered  suitable for use in a court of law. A  certificate  with the owner's
name,  reference and identification  number and other information will be mailed
back to the client.

The  reasons  for the use of the in home self test DNA  Profile  Kit and banking
service would include the  following:  1) storage of a person's DNA; 2) peace of
mind;  3)  permanent   identifier  of  family   member's  DNA;  4)  a  tool  for
identification  of missing  persons;  5) a genetic  history  of an elder  family
member  that may  provide  clues to  inherited  diseases;  and 6) other  genetic
issues.

CHAIN OF CUSTODY DNA PROFILING AND BANKING
Upon receipt of the client's  registration for the service, the Company will set
up a DNA sample collection appointment at a hospital,  laboratory or clinic near
the client.  At the time of  collection,  the client will be required to provide
identification in the form of birth certificate, social security card or drivers
license.  A DNA sample will be  collected  by way of a buccal cheek swab and the
client  will be  fingerprinted  and  photographed.  The sample  will be labeled,
securely  stored and then sent to an  independent  third party testing  facility
where  it  will be  analyzed  and a DNA  profile  will  be  determined,  thereby
establishing  the  DNA  pattern  in a  format  recognized  by the  international
scientific  and legal  communities.  We currently  intend to use Orchid  Helix's
testing  facilities to perform these services.  We have no agreement with Orchid
Helix.  This  collection  and testing  procedure  establishes a date and time of
submission as evidence of prior ownership.  The sample will be sealed and, along
with the results,  will be stored for a period of 20 years.  The results will be
cross  checked with our database for fraud and  duplicate  submissions  and then
added to our  database.  The Company  will provide the client with a DNA Profile
Bank  Certificate  outlining  the results of the client's  personal,  unique and
original DNA profile.

Results from home DNA tests are normally not guaranteed admissible in a court of
law due to the lack of the "chain of  custody".  The chain of custody  refers to
the legal  requirements  necessary to establish and document the various persons
and  methods  used to  handle  and  process  the  individual  sample.  A legally
admissible  "chain of custody" for a sample requires the samples to be collected
in the presence of a third neutral party at a lab or hospital facility where all
parties are photographed to verify their identity.

The  reasons  for the use of the Chain Of  Custody  DNA  Profiling  and  Banking
service  would  include  the  following;  1) Use as  evidence  of DNA  theft  or
misappropriation;  2) Proof of prior ownership; 3) Maternity or paternity cases;
or 4) Forensic cases.

We  estimate  the  entire  DNA  Process  for  either of the  services  will take
approximately four to eight weeks from the time of DNA sample collection.

These services will be charged by debit or credit card or purchased by cashier's
check or money order.

The  instructions  and examples on our website are  intended to allow  potential
consumers  to  quickly  begin  the DNA  collection  and  profiling  process  for
establishing their personal and unique DNA profile.

We plan to  process  most  orders  online by  online  credit  card or  cybercash
systems.  We currently are developing  the ability to process online orders.  In
addition we have researched the needs of our planned  website  functions and the
fees associated with the services needed to fulfill those needs.

Our  website  content  will  consist  of  information  relating  to the  biotech
industry,  in particular  content  dealing with cloning and its related  ethical
issues. More expansive information may be developed in the future.

DNA CLONING
We believe the cloning issue is confusing and fraught with ethical concerns.  We
plan to  provide  information  to help  simplify  the  issue  and  provide  more
expansive  information to familiarize  persons concerned about the cloning issue
and  protecting  their  personal  DNA  against  cloning.   The  process  of  DNA
collection, analysis and profiling can be an invasive, frightening and confusing
process for many. We believe we can  familiarize  the potential  client with the
required steps and the need for the Company's DNA profile and banking service

We believe it is  extremely  difficult to prevent a  determined  collector  from
obtaining  samples of DNA, since all complex living  creatures  constantly leave
traces of DNA throughout their  environment in the form of hair,  skin,  saliva,
etc. However,  we believe you can help deter persons who have illegally obtained
a sample of your DNA from  trafficking in these samples,  or in pursuing illegal
activities,  such as cloning of the samples,  by establishing  your personal DNA
profile to show prior ownership.

DISTRIBUTION

We plan to deliver  our  services  through our  website.  As of the date of this
prospectus, we have an Internet service provider, web site developer and a basic
web site,  all of which will be necessary  to execute our plan of  business.  We
plan to establish our market through email advertising and through licensing the
service to third parties on a geographic  basis; that is, we will grant licenses

<PAGE>

to persons or  business  entities to offer our  services  in  certain,  specific
geographic  areas,  such as, the Province of Alberta,  Canada..  We have not yet
established any specific geographic areas, and intend to do so only when we have
a third party  interested in obtaining a license for a specific  area. We do not
currently  have any licenses or licensees,  and have not been in contact with or
negotiated  with anyone for any such  license.  We have not conducted any market
testing to determine the size of the market for our services.

On July 15,  2003,  we entered  into a license  agreement  with Mr.  Matt Sutton
whereby we granted him a non-exclusive  license to market  services  relating to
the  collection of DNA samples and related data.  The agreement is for a term of
one (1) year,  commencing  August 15,  2003,  and the  license fee due under the
agreement is US$2,000.00 per month. The agreement with Mr. Sutton has terminated
and will not be renewed. Mr. Sutton made no sales of the Company's services. The
license  for Mr.  Sutton was not  renewed  because  he  decided to pursue  other
business  interests.  We do not  believe  this  lack of  renewal  will  have any
material  impact on the  Company.  As of June 30, 2005 the Company has  received
four (4) orders,  and sold and received  full payment for four(4) of its In Home
Self Test Kit.  The most  recent sale date for an In Home Self Test Kit was June
2005.  During the period ending June 30, 2005, the Company received  payments of
$7500 for the sale of additional in home test kits.  These in home test kits are
to be delivered by August 31st 2005.

NEW PRODUCTS OR SERVICES.

Other than the services  described in this prospectus,  we currently have no new
products or services announced or planned to be announced to the public.

COMPETITIVE BUSINESS CONDITIONS

We will face competition from all aspects of the emerging  DNA-related  business
and  industry.  We  will  compete  with  pharmaceutical  and  other  science  or
technology-related  companies that have superior  DNA-related  experience and/or
services  which they now,  or may, in the future,  offer to their  potential  or
existing  customers.  Many of these companies may in time offer free information
and DNA-related  storage facilities to their customers.  Many of these companies
have other  sources of revenues and we rely only on the fees  generated  through
our proposed DNA information and database services. In addition, these companies
may have better marketing and distribution  channels.  There can be no assurance
that we will be able to compete effectively in this highly competitive industry,
which  could  have a material  adverse  impact  upon  market  acceptance  of our
proposed business.

Our main,  existing  and  potential  competitors  for our  proposed DNA testing,
profiling and banking business are any business in the  pharmaceutical  business
or distribution of  pharmaceutical  products  business.  Some of the primary DNA
service and information  providers and competitors are: DNA Testing Centre, Inc.
-  www.dnatestingcentre.com,  GeneTree  DNA Testing  Center -  www.genetree.com,
Metaphase Genetics - www.metaphasegenetics.com, and Genex Diagnostics SwabTest -
WWW.SWABTEST.COM, and DNA Diagnostic Center - www.dnacenter.com

OUR COMPETITIVE POSITION

We  believe   competition  takes  place  on  many  levels,   including  pricing,
convenience in obtaining  information,  specialization,  and breadth of services
offered. We intend to serve as a content aggregator for DNA-related  information
on the  Internet,  and  provide  what we  believe is an  unbiased  comprehensive
information  source,  as well as marketplace  and  facilitator  for  DNA-related
information.

Our  objective  is to provide a service  that helps the consumer cut through the
often  perceived  clutter,  confusion and noise of the marketplace and help them
confidentially  and quickly  bring each person to a point where they can make an
informed decision if the services offered are appropriate for them.


Within the industry, we will attempt to brand our website WWW.YOURCLONEGUARD.COM
as the  consumer's  partner  in his or her  search  for the  most  reliable  DNA
collection,  profiling,  databank  and  information  source.  We will attempt to
provide the consumers with a one-stop shopping destination where they can access
information  and  decision  support  tools,  such as any related  news on topics
relating  to DNA.  However,  we  have no  assurance  we  will be  successful  in
differentiating ourselves from our competitors, or that we will be successful in
providing  acceptable services or competing in the marketplace for our services.
We will be using the  Internet  to  advertise  our  services,  by  paying  other
websites to place a link to our website on their website. We anticipate the cost
of this form of  advertising  will cost  approximately  $2,000  over the next 12
months.


By  offering a  specialized  DNA  storage and  information  service,  we will be
targeting  those  consumers  who are looking to establish  their DNA profile and
banking of that profile.  We believe that  consumers will pay for a service that
is specialized,  unbiased and  comprehensive and one that helps them cut through
the perceived clutter,  confusion and noise of the internet marketplace and help
them confidentially and quickly make an informed decision if the DNA testing and
profiling services offered are appropriate for them.


We expect  that our  operations  will depend on a number of third  parties  over
which  we will  have  limited  control.  Specifically,  we do not plan to own an
Internet  gateway,  but instead we will rely on a third-party,  independent  and
unrelated  Internet  Service  Provider to host our  website.  We may  experience

<PAGE>

interruptions in our website connection and our telecommunications access due to
our  reliance  upon third  parties.  This could  result in loss of business  and
revenues.  We  anticipate  that we will use  software  that is  dependent  on an
operating  system,  database and server  software  developed and produced by and
licensed by  independent  third parties.  We may discover  errors and defects in
this third party  software and rely on the third parties to correct these errors
and  defects  in  a  timely   manner.   Accordingly,   continuous  or  prolonged
interruptions  in our website  connection  or in our  telecommunications  access
would have an adverse effect upon consumer  perception of our ability to provide
information in a timely and efficient manner.


A party who is able to circumvent  our security  measures  could  misappropriate
proprietary information and/or access our customers' DNA-related information and
data. We may be required to expend  significant  capital and other  resources to
protect against security  breaches or to alleviate  problems caused by breaches.
Concerns over the security of Internet transactions and the privacy of users may
also  inhibit the growth of the  Internet  generally,  and the World Wide Web in
particular,  especially as a means of conducting commercial transactions. To the
extent that our future  activities or those of third party  contractors  whom we
may use involve the storage and transmission of proprietary information, such as
DNA-related  information  and data and credit card  numbers,  security  breaches
could expose us to a risk of loss or litigation.  There can be no assurance that
we will be able to  implement  security  measures  that  will  prevent  security
breaches.

SOURCES AND AVAILABILITY OF RAW MATERIALS

As of the date of this prospectus,  we have established initial contact with DNA
sample kit  suppliers and DNA testing  facilities.  We have not entered into any
arrangement or agreements to date.

CUSTOMER BASE

As ofAugust 9, 2005, the Company has received four (4) orders, amounting to $480
in sales  revenue,  for its In Home Self Test Kit. We have  received  payment in
full of the  $480.  We do not  anticipate  we will  depend on one or a few major
customers. There can be no assurance that this assumption is correct.

Our intended  principal market of customers is expected to be the people who are
aware of the problem with identity  theft,  those with concerns about the health
and health risk factors of their relatives and unborn children and those wishing
to  preserve  their DNA  profile  in a data bank for future  uses.  We intend to
target this market  using  internet  advertising  and  promotion  of our website
through links on other health- related websites,  which we currently  anticipate
will cost us  approximately  $2,000 over the next 12 months.  Although we cannot
clearly  determine or identify  those who may see our marketing  efforts or seek
our services,  we believe that persons visiting these websites could be included
in our  target  market.  We do not feel that the costs to  advertise  and market
through  the  internet  is a barrier to our  entry.  We have not  performed  any
marketing  studies to assess whether a potential  market exists for our proposed
services,  but we believe that there is such a market based on the  existence of
other  web-based  data banks and the number of  articles  about DNA  storage and
identity theft management has seen in the media. We do not intend to perform any
marketing studies prior to beginning  operations.  Based on the costs of similar
services, we believe we can sustain a market for our services.


INTELLECTUAL PROPERTY

We have recently applied for a service mark for "yourcloneguard". We do not have
any trademarks,  patents,  licenses,  royalty  agreements,  or other proprietary
interests, except for the web domain name: YOURCLONEGUARD.COM.

GOVERNMENTAL REGULATION ISSUES

We are not now affected by direct government regulation.  Based on our research,
we do not believe the products and services we intend to offer require  approval
from the Food and Drug  Administration.  However, we are affected by laws, rules
and  regulations  directly  applicable  to access to or commerce on the Internet
generally.  However,  due to increasing usage of the Internet,  a number of laws
and regulations may be adopted relating to the Internet,  covering user privacy,
pricing, and characteristics and quality of products and services.  Furthermore,
the growth and  development  for  Internet  commerce  may prompt more  stringent
consumer   protection  laws  imposing  additional  burdens  on  those  companies
conducting  business over the Internet.  The adoption of any additional  laws or
regulations  may  decrease the growth of the  Internet,  which,  in turn,  could
decrease  the  demand  for  Internet  services  and  increase  the cost of doing
business  on the  Internet.  These  factors  may have an  adverse  effect on our
business, results of operations and financial condition.

Moreover,  the  interpretation  of sales tax,  libel and  personal  privacy laws
applied to Internet commerce is uncertain and unresolved.  We may be required to
qualify  to do  business  as a  foreign  corporation  in each  state or  foreign
country. Our failure to qualify as a foreign corporation in a jurisdiction where
we are required to do so could subject us to taxes and  penalties.  Any existing
or new legislation or regulation,  including state sales tax, or the application
of laws or regulations from  jurisdictions  whose laws do not currently apply to
our business,  could have a material adverse effect on our business,  results of
operations and financial condition.


<PAGE>

MARKETING RESEARCH AND DEVELOPMENT

To date,  we have spent  $10,000 on marketing  research and  development  of our
website.


ENVIRONMENTAL LAW COMPLIANCE

To  the  extent  which  environmental  compliance  may be  necessary,  we do not
anticipate any significant compliance expense.

EMPLOYEES.

The Company does not have any employees.

REPORTS TO SECURITY HOLDERS.

As of February 11, 2005 the Company became effective and is a reporting  company
under the  requirements of the Exchange Act and will file quarterly,  annual and
other reports with the  Securities  and Exchange  Commission.  Our annual report
will contain the required audited financial  statements.  We are not required to
deliver an annual report to security holders and will not voluntarily  deliver a
copy of the  annual  report  to the  security  holders.  The  reports  and other
information  filed by us will be  available  for  inspection  and copying at the
public  reference  facilities  of  the  Commission,   450  Fifth  Street,  N.W.,
Washington, D.C. 20549.

Copies of the material may be obtained by mail from the Public Reference Section
of the  Commission  at 450  Fifth  Street,  N.W.,  Washington,  D.C.  20549,  at
prescribed rates.  Information on the operation of the Public Reference Room may
be obtained by calling the SEC at  1-800-SEC-0330.  In addition,  the Commission
maintains  a World  Wide  Website on the  Internet  at  http://www.sec.gov  that
contains  reports,  proxy  and  information  statements  and  other  information
regarding registrants that file electronically with the Commission.


PLAN OF OPERATIONS

The  discussion   contained  in  this   prospectus   contains   "FORWARD-LOOKING
STATEMENTS"  that  involve  risk  and  uncertainties.  These  statements  may be
identified  by the use of  terminology  such as  "BELIEVES,"  "EXPECTS,"  "MAY,"
"SHOULD" or "ANTICIPATES"  or expressing this terminology  negatively or similar
expressions  or by discussions of strategy.  The cautionary  statements  made in
this  prospectus  are  applicable  to  all  related  forward-looking  statements
wherever  they  appear in this  prospectus.  Our  actual  results  could  differ
materially from those discussed in this prospectus. Important factors that could
cause or  contribute to these  differences  include  those  discussed  under the
caption  entitled "RISK FACTORS," as well as those  discussed  elsewhere in this
registration statement.

We are a development stage company with limited  operations or revenues.  We are
unable to satisfy cash requirements  without  management's  financial support or
other  funding.  Our  management  and certain  investors  have made  $149,975 of
capital  contributions  to our  business.  The  Company  has raised the total of
$99,975 through Private Placements (see page 32 of the SB-2 filing "Recent Sales
of  Unregistered  Securities")  and in  January of 2004 the  Company  issued two
convertible  debentures in the principal  amount of $25,000 each, at an interest
rate of 10% per annum,  for a total principal  amount of $50,000 to two separate
unrelated  non-US  parties.  Subsequent  to June  30,  2005,  these  convertible
debentures have been converted to the number of shares stated in the financials.
We  anticipate,  but  have no  assurance,  that we may  need  to meet  our  cash
requirements  for the  foreseeable  future through the financial  support of our
management.  Management's  capital  contributions  will be accomplished  through
interest bearing  promissory  notes between our company and management.  We have
not  determined  the amount of funds that will be necessary  for  management  to
contribute at this time.  Nor is there any assurance  our  management  will have
funds  available to loan us as and when we require funds. In this event, we will
be required to seek loans and/or equity funding from third parties, and there is
no assurance we will be able to do so.

The Company's website will be used as a marketing and sales tool. It is intended
to outline  the  features  and the  benefits of the DNA  collection  and profile
service  as well as acting as an  information  resource.  The  instructions  and
examples on our website are  intended to allow  potential  consumers  to quickly
begin the DNA collection and profiling  process for establishing  their personal
and unique DNA profile.

We anticipate that most orders for our services will occur by online credit card
or cybercash  systems.  We can take orders online through our order form and are
currently developing the ability to process online orders.

Over  the  next  twelve  months,   we  plan  to  further   develop  our  website
WWW.YOURCLONEGUARD.COM   to  provide   additional   DNA   related   information.
Specifically,  during the next 12 months, we anticipate  focusing our efforts on
the following specific areas of operations:
         1. Internet marketing
         2. Maintaining and enhancing content of website
         3. Licensing agreements
         4. DNA information and services

<PAGE>


In the event we need to raise additional  funds, we have not yet determined how,
where or when we will obtain these funds.  There is no assurance that we will be
able to obtain financing for our business development, if, as and when required,
or on terms favorable to the Company. If adequate funds are not available to us,
we believe that our business development could be adversely affected. To sustain
operations over the next 12 months we are anticipating total operational expense
of $14,000 made up as follows $2000  internet  advertising  and  promotion,  and
$12,000 for marketing and operational expenses.

As of June 30, 2005 the Company had available  cash in the amount of $10,095 and
accounts  receivables  in the  amount of  $2,000.  Our cash will be used to fund
operations until approximately the end of December 2005. During the period prior
to December 2005, the Company may, nevertheless, need to seek additional funding
in the form of equity or debt to meet unanticipated expenses.

Our future capital requirements will also depend on one or more of the following
factors:  - market acceptance of our services;  - the extent and progress of our
research  and  development  programs;  -  competing   technological  and  market
developments; and - the costs of commercializing our services.

There can be no assurance  that funding will be available on favorable  terms to
permit successful  commercialization of our DNA services or be successful in our
proposed business operations.

In addition,  we have no further credit facility or other  committed  sources of
capital.  We may be unable to  establish  credit  arrangements  on  satisfactory
terms,  if at all.  If capital  resources  are  insufficient  to meet our future
capital  requirements,  we may  have  to  raise  additional  funds  to  continue
development  of our website.  There can be no  assurance  that the funds will be
available on favorable terms, if at all.

To the  extent  that  additional  capital is raised  through  the sale of equity
and/or  convertible debt securities,  the issuance of the securities will likely
result in dilution to our shareholders.

Our website is fully developed,  operational and is producing revenue. The total
cost for  developing  our website was $2,157.  We  anticipate  we will  generate
revenues from the  accumulation  of customer's  DNA  information  and data, in a
legal state, to the website, and through the sale of advertisements. There is no
assurance  that we will be successful in the marketing our DNA profile  services
or licensing. We have no other proposed sources of revenue. Therefore, if we are
not successful in this regard,  we will be unable to achieve  revenues under our
current business plan.

If our  company  or its  management  receives  proceeds  from  the  sales of the
securities by the selling security  shareholders,  which neither the company nor
its management has any intent to do, those persons may have conducted an illegal
distribution of our securities and may be deemed underwriters. Accordingly, they
will have  liability  for any material  misrepresentations  or omissions in this
document and otherwise in the offer and sale of securities.

We do not anticipate significant research and development expenses over the next
twelve  months.  We do not expect to purchase or sell any plant and  significant
equipment or make any  significant  changes in the number of employees  over the
next twelve months.

DESCRIPTION OF PROPERTY

We do not own any real  property at this time,  and we conduct our business from
an office at 2890 Vassar Street, Suite A, Reno, NV 89502. We are sharing a small
office space at no cost with an unrelated  third  party.  This is a  competitive
rate for similar space in the area.

The Company believes that existing facilities are adequate for its needs through
December  2005.  Should the Company  require  additional  space at that time, or
prior  thereto,  the Company will  attempt to secure  space can on  commercially
reasonable terms and without undue operational disruption.

<PAGE>



PART II       OTHER INFORMATION

ITEM 7. SIGNATURES


                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.


                             BV PHARMACEUTICAL, INC.



         DATE: AUGUST 11, 2005       BY: /s/ ART BANDENIEKS
                                             -----------------------------
                                             ART BANDENIEKS, PRESIDENT AND
                                             DIRECTOR